Maria Piron1,2,3, Mireia Jané4,5,6, Pilar Ciruela4,5, Luca Basile4, Ana Martínez4,5, Lluis Puig1,2, Marta Bes1,2,3, Silvia Sauleda1,2,3. 1. Blood and Tissue Bank, Transfusion Safety Laboratory, Barcelona, Spain. 2. CIBER Liver and Digestive Diseases (CIBERHED), Institute of Health Carlos III, Madrid, Spain. 3. Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron University Hospital, Barcelona, Spain. 4. Public Health Agency of Catalonia, Barcelona, Spain. 5. CIBER Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain. 6. University of Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: Due to the COVID-19 pandemic, a national lockdown was applied in Spain from March to May 2020. It is uncertain when SARS-CoV-2 started to circulate in Catalonia, and only a few cases were diagnosed in this period. We assessed the SARS-CoV-2 seroprevalence in blood donors before and after the first wave and compared it with public health service (PHS) data. MATERIALS AND METHODS: Retrospective archive or prospective fresh blood samples were obtained from blood donors aged 18 to 70 and anonymized after demographic data had been recorded (gender, age, place of residence, blood collection date). Two CE-marked enzyme-linked immunosorbent assays were used to test for anti-SARS-CoV-2. A SARS-CoV-2 IgM test was additionally performed in positive samples. Individuals aged 18 to 70 from among the general population diagnosed as having SARS-CoV-2 by the PHS were included for comparison with blood donor results. RESULTS: A total of 10,170 blood donations were included in the first period, between 24 February and 9 March 2020, and 6,829 in the second period, between 16 May and 17 June 2020. The observed SARS-CoV-2 seroprevalence among blood donors rose from 0.27% (95% CI: 0.18-0.39) before the first wave to 5.55% (95% CI: 5.03-6.12) after it, and was even higher (6.90% [95% CI: 5.64-8.41]) among blood donors aged 18 to 29. The seroprevalence among blood donors was higher in more populated areas (Barcelona: 7.69%). A comparison of blood donor data with officially diagnosed cases showed a global 87.44% underestimation of SARS-CoV-2 in June 2020. DISCUSSION: We analyzed the explosive 3-month increase in blood donor SARS-CoV-2 seroprevalence (from 0.27% to 5.55%) and show that more than 87% of cases went undiagnosed, despite the unprecedented deployment of testing measures. SARS-CoV-2 IgM results suggest that the virus was circulating among blood donors in February 2020. Blood donors are definitively proven to be a valuable resource for emerging disease surveillance studies.
BACKGROUND: Due to the COVID-19 pandemic, a national lockdown was applied in Spain from March to May 2020. It is uncertain when SARS-CoV-2 started to circulate in Catalonia, and only a few cases were diagnosed in this period. We assessed the SARS-CoV-2 seroprevalence in blood donors before and after the first wave and compared it with public health service (PHS) data. MATERIALS AND METHODS: Retrospective archive or prospective fresh blood samples were obtained from blood donors aged 18 to 70 and anonymized after demographic data had been recorded (gender, age, place of residence, blood collection date). Two CE-marked enzyme-linked immunosorbent assays were used to test for anti-SARS-CoV-2. A SARS-CoV-2 IgM test was additionally performed in positive samples. Individuals aged 18 to 70 from among the general population diagnosed as having SARS-CoV-2 by the PHS were included for comparison with blood donor results. RESULTS: A total of 10,170 blood donations were included in the first period, between 24 February and 9 March 2020, and 6,829 in the second period, between 16 May and 17 June 2020. The observed SARS-CoV-2 seroprevalence among blood donors rose from 0.27% (95% CI: 0.18-0.39) before the first wave to 5.55% (95% CI: 5.03-6.12) after it, and was even higher (6.90% [95% CI: 5.64-8.41]) among blood donors aged 18 to 29. The seroprevalence among blood donors was higher in more populated areas (Barcelona: 7.69%). A comparison of blood donor data with officially diagnosed cases showed a global 87.44% underestimation of SARS-CoV-2 in June 2020. DISCUSSION: We analyzed the explosive 3-month increase in blood donor SARS-CoV-2 seroprevalence (from 0.27% to 5.55%) and show that more than 87% of cases went undiagnosed, despite the unprecedented deployment of testing measures. SARS-CoV-2 IgM results suggest that the virus was circulating among blood donors in February 2020. Blood donors are definitively proven to be a valuable resource for emerging disease surveillance studies.
Authors: Marina Pollán; Beatriz Pérez-Gómez; Roberto Pastor-Barriuso; Jesús Oteo; Miguel A Hernán; Mayte Pérez-Olmeda; Jose L Sanmartín; Aurora Fernández-García; Israel Cruz; Nerea Fernández de Larrea; Marta Molina; Francisco Rodríguez-Cabrera; Mariano Martín; Paloma Merino-Amador; Jose León Paniagua; Juan F Muñoz-Montalvo; Faustino Blanco; Raquel Yotti Journal: Lancet Date: 2020-07-06 Impact factor: 79.321
Authors: Corine H GeurtsvanKessel; Nisreen M A Okba; Zsofia Igloi; Susanne Bogers; Carmen W E Embregts; Brigitta M Laksono; Lonneke Leijten; Casper Rokx; Bart Rijnders; Janette Rahamat-Langendoen; Johannes P C van den Akker; Jeroen J A van Kampen; Annemiek A van der Eijk; Rob S van Binnendijk; Bart Haagmans; Marion Koopmans Journal: Nat Commun Date: 2020-07-06 Impact factor: 14.919
Authors: Gayatri Amirthalingam; Heather Whitaker; Tim Brooks; Kevin Brown; Katja Hoschler; Ezra Linley; Ray Borrow; Colin Brown; Nick Watkins; David J Roberts; Danielle Solomon; Charlotte M Gower; Olivier le Polain de Waroux; Nick J Andrews; Mary E Ramsay Journal: Emerg Infect Dis Date: 2021-07 Impact factor: 6.883
Authors: Silvia Stringhini; Ania Wisniak; Giovanni Piumatti; Andrew S Azman; Stephen A Lauer; Hélène Baysson; David De Ridder; Dusan Petrovic; Stephanie Schrempft; Kailing Marcus; Sabine Yerly; Isabelle Arm Vernez; Olivia Keiser; Samia Hurst; Klara M Posfay-Barbe; Didier Trono; Didier Pittet; Laurent Gétaz; François Chappuis; Isabella Eckerle; Nicolas Vuilleumier; Benjamin Meyer; Antoine Flahault; Laurent Kaiser; Idris Guessous Journal: Lancet Date: 2020-06-11 Impact factor: 79.321
Authors: Roberto Pastor-Barriuso; Beatriz Pérez-Gómez; Miguel A Hernán; Mayte Pérez-Olmeda; Raquel Yotti; Jesús Oteo-Iglesias; Jose L Sanmartín; Inmaculada León-Gómez; Aurora Fernández-García; Pablo Fernández-Navarro; Israel Cruz; Mariano Martín; Concepción Delgado-Sanz; Nerea Fernández de Larrea; Jose León Paniagua; Juan F Muñoz-Montalvo; Faustino Blanco; Amparo Larrauri; Marina Pollán Journal: BMJ Date: 2020-11-27
Authors: Helen Ward; Christina Atchison; Matthew Whitaker; Kylie E C Ainslie; Joshua Elliott; Lucy Okell; Rozlyn Redd; Deborah Ashby; Christl A Donnelly; Wendy Barclay; Ara Darzi; Graham Cooke; Steven Riley; Paul Elliott Journal: Nat Commun Date: 2021-02-10 Impact factor: 14.919